TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02956837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3003891A) formulation 1
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3003891A) formulation 2
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3003891A) formulation 3
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Formulation buffer S9b)
Description: A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
Study: NCT00269321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic Manual treatment + home exercise (procedure+behavior)
Description: The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitative exercise+home exercise
Description: The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
Study: NCT00867984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Torsion optimized
Description: Torsion optimized VV timing plus AV optimization (VTI)
Study: NCT03172377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lengthening adalimumab dosing interval
Description: Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.
Study: NCT00003832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromodeoxyuridine
Description: Given IV
Study: NCT00867984

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: AV optimization (VTI) only
Study: NCT01727505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sequence A: Conventional-Volume Guarantee
Description: This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence A, the infant will undergo a 24-hour period of conventional mechanical ventilation followed by a 24 hour period of volume guarantee ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sequence B: Volume Guarantee-Conventional
Description: This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence B, the infant will undergo a 24-hour period of volume guarantee ventilation followed by a 24 hour period of conventional mechanical ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study.
Study: NCT00990444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin in Dextran Matrix
Description: Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin in Dextran Matrix
Description: Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
Study: NCT05037643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Transjugular Intrahepatic Portosystemic Shunt is performed to prevent / treat symptomatic portal hypertension
Study: NCT02892643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic proximal gastrectomy
Description: Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic total gastrectomy
Description: Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
Study: NCT04001647

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcholine
Description: Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Nitroprusside
Description: Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
Study: NCT03842540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SpeakOut
Description: SpeakOut aims to increase social communication about contraception between adolescent IUD and implant users and their peers. SpeakOut has four components:~1. Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~2. Digital materials for recipients to keep and/or share with friends.~3. Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~4. Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PartyWise
Description: The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. Staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
Study: NCT01424813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Description: Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Study: NCT00786552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed + paclitaxel
Description: Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
Study: NCT01770795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM/Gemcitabine
Study: NCT02278484

Intervention type: DEVICE
Group type: OTHER
Intervention: XprESS device and PathAssist confirmation tools
Study: NCT00513708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation Enhancement Therapy (MET)
Description: Participants assigned to this arm will receive a 60-minute MET intervention in addition to usual care while hospitalized for detoxification.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Twelve Step Facilitation (P-TSF)
Description: In addition to usual care while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are recovering from alcoholism and who are active in 12-step oriented self-help programs.
Study: NCT00003832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02425462

Intervention type: DRUG
Intervention: Dienogest (Visanne, BAY86-5258)
Description: Dienogest 2mg daily Oral dose
Study: NCT00385827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: Mitoxantrone 12 mg/m\^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone 12 mg/m\^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2)
Study: NCT04283890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab and nivolumab
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan chemosaturation via percutaneous hepatic perfusion
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan chemosaturation via percutaneous hepatic perfusion
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan chemosaturation via percutaneous hepatic perfusion
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
Study: NCT02741453

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral IJ Ultrasound Scanning
Study: NCT01701102

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine (24 mg) plus fentanyl
Description: Mepivacaine (24 mg) and fentanyl (10 µg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine (27 mg) plus fentanyl
Description: Mepivacaine (27 mg) and fentanyl (10 µg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine (30 mg) plus fentanyl
Description: Mepivacaine (30 mg) and fentanyl (10 µg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: Mepivacaine 37.5 mg
Study: NCT02391142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
Study: NCT00250744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant vs. Gabapentin
Description: Gabapentin 300mg PO QHS day -2; 300mg PO BID day -1; 300mg PO TID days 0 through +5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant vs. Gabapentin
Description: Aprepitant 125mg PO 60 minutes prior to chemotherapy on day 0; 80 mg PO QAM on days +1 and +2.
Study: NCT02920970

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: contact lens
Study: NCT00788970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure adjuvant therapy
Description: Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acupressure adjuvant therapy
Description: Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
Study: NCT01969851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).~Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively.
Study: NCT02269423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline placebo.
Study: NCT00208559

Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone
Description: Ziprasidone 40mg to 60mg per day, individually titrated
Study: NCT00391703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electrostimulation programme: using a cycloergometer
Description: Quadriceps electrostimulation programme performed prior to an endurance retraining program using a cycloergometer, for 6 weeks, 60 to 90 minutes by session, 5 to 6 sessions per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual sport activity
Description: Usual sport activity performed prior to an endurance retraining program using a cycloergometer
Study: NCT02221557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: easy-graft (beta-Tricalcium Phosphate)
Study: NCT03731897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.
Description: Plantar fascia will be injected to the places where it adheres to the bone.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 9 cc salin + 1cc 2% lidocaine.
Description: Plantar fascia will be injected to the places where it adheres to the bone.
Study: NCT02847039

Intervention type: GENETIC
Intervention: Blood samples
Description: Blood samples at baseline.
Study: NCT04176731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod Horizon™ Automated Glucose Control System
Description: The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
Study: NCT02389764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Initial dose is 200 mg twice daily orally for a 28 day cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.
Study: NCT04518046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
Study: NCT01424605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DLT intubation
Description: Using a video-assisted laryngoscope to facilitate endotracheal tube intubation
Study: NCT00276198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles
Description: Daily dosage of fat coated iron (desote fumarate) 12.5 mg, zinc 5mg, vitamin A 300 micrograms, folic acid 150 micrograms, ascorbic acid 50 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferripel-3, Vitamins A&D drops
Description: Daily dosage of Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms once a day from age 6 months up to age 12 months
Study: NCT01549834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: Low Dose
Study: NCT00385827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone 12 mg/m\^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 5 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg orally twice daily
Study: NCT04028791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise on ergocycle
Description: The exercise includes 15 minutes of warm up, then participants will be asked to pedal as fast as possible for 6 seconds. The test of 6 seconds will be repeated twice or more with recovery each time